血管性血友病（VWD）：市場展望、流行病學、競爭格局、市場預測報告，2026-2036年

市場概覽

• 預計西班牙VWD市場將從2026年的5,500萬美元成長到2036年的9,500萬美元。
• 以下因素正在推動市場成長：
• 擴大因子替代療法和標靶治療的應用
• 改善診斷和疾病管理
• 未來的發展取決於能否提供能夠持續預防出血和改善患者預後的治療方法。

血管性血友病（VWD）市場展望及預測

血管性血友病（VWD）概述

血管性血友病是一種遺傳性出血性疾病，由血管性血友病因子（VWF）的數量不足或品質功能障礙引起，導致血小板黏附受損，部分患者也可能影響VIII因子的穩定性。臨床嚴重程度差異很大，從輕微的黏膜出血到嚴重的複發性出血不等。目前的治療方法包括去氨加壓素、含VWF的濃縮製劑、對有效患者進行抗纖溶治療，以及對某些嚴重或頻繁出血的患者進行預防性治療。治療前景已超越了間歇性血漿替代療法。重組VWF產品Vonicog alfa於2025年獲得FDA批准，用於所有類型VWD成人患者的常規預防性治療，其適應症範圍擴大；而Wilate將於2026年獲得FDA進一步擴大適應症，使其適用於6歲以下兒童的常規預防性治療。這些進展正推動治療研發朝著減少治療頻率和輸液負擔的方向發展，同時維持持續的止血效果。新的治療方法包括延長VWF暴露時間的藥物，例如HMB-002；針對特定2B型疾病的標靶治療，例如rondoraptivon pegol；以及調節止血平衡的策略，例如VGA039。雖然這些方法仍處於研究階段，但它們正在拓展該領域的應用範圍，使其超越直接VWF替代療法。對於相關人員，VWD是罕見血液疾病領域中一個極具價值的研究方向，未來的發展很可能將延長藥物作用時間、減輕給藥負擔以及根據作用機制客製化止血控制策略相結合。

主要亮點

• 在西班牙，預計 VWD 的診斷數量將從 2026 年的 708 例增加到 2036 年的 789 例。
• 血管性血友病（VWD）是一種常見的遺傳性出血性疾病，由血管性血友病因子缺乏或缺陷所引起。
• 出血事件和疾病的嚴重程度因人而異。
• 目前仍有大量未被滿足的需求，即缺乏能夠有效且持續控制出血的治療方法。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Hoffmann-La Roche
• Vega Therapeutics, Inc.
• Octapharma
• Takeda
• Hemab ApS
• Shanghai RAAS Blood Products Co., Ltd.
• Bioverativ, a Sanofi company
• Alnylam Pharmaceuticals

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並正在接受藥物治療的患者族群。
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 目前主要療法－概述及關鍵意見領袖見解
• 新興療法
• 重點
• 值得關注的後期新興療法—概述、上市預期和關鍵意見領袖見解
• 值得關注的早期管道

第6章：未滿足的需求與TPP分析

• 新興療法的關鍵未滿足需求和未來成就前景
• TPP分析與KOL預期

第7章 監理與報銷環境

第8章附錄

Von Willebrand Disease Market Outlook and Forecast

Thelansis's "Von Willebrand Disease (VWD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Von Willebrand Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Von Willebrand Disease (VWD) Overview

Von Willebrand disease is an inherited bleeding disorder caused by quantitative deficiency or qualitative dysfunction of von Willebrand factor, impairing platelet adhesion and, in some patients, factor VIII stability. Clinical severity varies widely, ranging from mild mucosal bleeding to severe recurrent hemorrhage. Current treatment includes desmopressin in responsive patients, VWF-containing concentrates, antifibrinolytic therapy, and prophylaxis for selected patients with severe or frequent bleeding. The therapeutic landscape has already advanced beyond episodic plasma-derived replacement: recombinant VWF vonicog alfa is FDA-approved for routine prophylaxis in adults with all VWD types, following a 2025 indication expansion, while Wilate received a further FDA expansion in 2026 to include routine prophylaxis in children younger than 6 years. These advances are shifting development toward reducing treatment frequency and infusion burden while maintaining sustained hemostatic protection. Emerging approaches include agents that prolong VWF exposure, such as HMB-002, targeted therapies such as rondoraptivon pegol for selected type 2B disease, and hemostatic rebalancing strategies such as VGA039. These approaches remain investigational, but they broaden the field beyond direct VWF replacement. For stakeholders, VWD represents a high-value rare-hematology opportunity where the next advances are likely to combine longer duration, less burdensome administration, and mechanism-specific hemostatic control.

Key Highlights

• In Spain, diagnosed VWD cases are projected to increase from 708 in 2026 to 789 by 2036.
• Von Willebrand Disease (VWD) is a common inherited bleeding disorder caused by deficient or defective von Willebrand factor.
• Bleeding episodes and disease severity vary widely across patients.
• Significant unmet need remains for therapies providing effective and sustained bleeding control.

Market Overview

• The Spain VWD market is projected to grow from $55M in 2026 to $95M by 2036.
• Market growth is driven by:
• Increasing adoption of factor replacement and targeted therapies
• Improved diagnosis and disease management
• Future growth will depend on therapies offering durable bleeding prevention and improved patient outcomes.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2026-2036)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Hoffmann-La Roche
• Vega Therapeutics, Inc.
• Octapharma
• Takeda
• Hemab ApS
• Shanghai RAAS Blood Products Co., Ltd.
• Bioverativ, a Sanofi company
• Alnylam Pharmaceuticals

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)